Abstract:Background Current treatment recommendations for resectable or borderline pancreatic carcinoma support upfront surgery and adjuvant therapy. However, neoadjuvant therapy (NT) seems to increase prognosis of pancreatic carcinoma and come to everyone’s attention gradually. Randomized controlled trials offering comparison with the NT are lacking and optimal neoadjuvant treatment regimen still remains uncertain. This study aims to compare both treatment strategies for resectable or borderline resectable pancreatic cancer. Methods The PRISMA checklist was used as a guide to systematically review relevant peer-reviewed literature reporting primary data analysis. We searched PubMed, Medline, EMBASE, Cochrane Datebase and related reviews for randomized controlled trials comparing neoadjuvant therapy with surgery first for resectable or borderline resectable pancreatic carcinoma. We estimated relative hazard ratios (HRs) for median overall survival and ratios risks (RRs) for microscopically complete (R0) resection among different neoadjuvant regimens and major complications. We assessed the effects of neoadjuvant therapy on R0 resection rate and median overall survival with Bayesian analysis. Results Thirteen eligible articles were included. Eight studies performed comparison neoadjuvant therapy with surgery first, and R0 resection rate was recorded in seven studies. Compared with surgery first, neoadjuvant therapy did increase the R0 resection rate (RR = 1.53, I 2 = 0%, P< 0.00001), there was a certain possibility that gemcitabine + cisplatin (Gem+Cis) + Radiotherapy was the most favorable in terms of the fact that there was no significant difference concerning the results from the individual studies. In direct comparison, four studies were included and estimated that Neoadjuvant therapy improved mOS compared with upfront surgery (HR 0.68, 95% CI 0.58–0.92; P = 0.012; I 2 = 15%), after Bayesian analysis it seemed that regimen with Cisplatin/ Epirubicin then Gemcitabine/ Capecitabine (PEXG) was most likely the best with a relatively small sample size. The rate of major surgical complications was available for six studies and ranged from 11% to 56% with neoadjuvant therapy and 11% to 45% with surgery first. There was no significant difference between neoadjuvant therapy and surgery first, also with a high heterogeneity (RR = 0.96, 95%CI = 0.65–1.43; P = 0.85; I 2 = 46%). Conclusion In conclusion neoadjuvant therapy might offer benefit over up-front surgery. Neoadjuvant therapy increased the R0 resection rate with gemcitabine + cisplatin + Radiotherapy that was the most favorable and improved mOS with Cisplatin/ Epirubicin then Gemcitabine/ Capecitabine (PEXG) that was most likely the best.

Evaluation of neoadjuvant therapy for pancreatic cancer: is it the best choice?

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Emphasis on Neoadjuvant Therapy for “resectable”pancreatic Cancer

Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer

Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials

Neoadjuvant Therapy for Resectable Pancreatic Cancer: a Narrative Review

Current Status and Perspectives of Neoadjuvant Therapy for Pancreatic Cancer

New advances in the treatment of pancreatic carcinoma

Neoadjuvant treatment for pancreatic cancer: Controversies and advances

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

[Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].

Neoadjuvant and Adjuvant Therapy in Resectable Pancreatic Adenocarcinoma

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature

[Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer]

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study

Thinking in the confusion, advancing in the challenges:hotspots in the comprehensive treatment of pancreatic carcinoma

Highlights and difficulties in surgical treatment for pancreatic carcinoma

[Effects of Neoadjuvant Therapy on Postoperative Complication of Pancreatic Cancer Surgery].

Concept renovation and technical progress in surgical treatment of pancreatic cancer